Novel Health Strategies team is presenting 15 studies at ISPOR Annual Meeting in Montreal, Canada on market access strategy, pricing and health economic and outcomes research trends.

These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.

In-person replays of all presentations are available upon request

PCN161: Systematic Review of Patient Reported Outcomes in Chronic Myeloid Leukemia

PCN162: Patient Reported Outcomes In Metastatic Castration-Resistant Prostate Cancer

PSY3: Meta-Analysis of Efficacy of Romiplostim for Treatment of Immune Idiopathic Thrombocytopenia

PHP194: Systematic Review on Use of Economic Evidence by Clinical Guidelines

PSS42: A Systematic Review of Patient Reported Outcomes in Glaucoma

PMS7: Meta-Analysis of Efficacy of Etanercept for Treatment of Psoriatic Arthritis

PCV17: Meta-Analysis of Safety of Dabigatran and Warfarin for Treatment of Atrial Fibrillation

PCN204: Novel Market Access Models for Cancer Drugs

PHP52: Importance of Subgroup Analyses for Health Technology Assessments

PUK11: In-Patient Hospitalizations for Chronic Kidney Disease in the United States